查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012697

自體免疫疾病治療市場：2026-2032年全球市場預測（依藥物類別、作用機制、給藥途徑、適應症、最終用戶及通路分類）

Autoimmune Disease Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自體免疫疾病治療市場價值將達到 1,258.6 億美元，到 2026 年將成長至 1,356.4 億美元，到 2032 年將達到 2,221.9 億美元，年複合成長率為 8.45%。

主要市場統計數據
基準年 2025 1258.6億美元
預計年份：2026年 1356.4億美元
預測年份 2032 2221.9億美元
複合年成長率 (%) 8.45%

概述了臨床創新、商業性複雜性和政策因素如何共同重新定義自體免疫疾病的治療策略。

本執行摘要概述了目前重塑自體免疫疾病治療格局的臨床、商業性和政策趨勢。內容涵蓋了治療方法的進展、作用機制的演變、給藥途徑的改變以及分銷和醫療服務模式的轉變。本文重點闡述了科學創新如何與報銷壓力、供應鏈脆弱性以及患者對以患者為中心的醫療服務日益成長的期望相互交織，從而形成一個需要靈活應對的複雜環境。

科學突破、支付方壓力和以患者為中心的醫療保健服務模式如何相互作用，重新定義自體免疫疾病治療領域的競爭格局和臨床動態。

自體免疫治療領域正經歷一系列變革，其驅動力來自科學進步、監管法規的演變以及患者和支付方期望的轉變。治療方法不再只是漸進式的改進，而是涵蓋了新型生物製藥、選擇性日益增強的細胞激素抑制劑以及挑戰傳統腸外給藥優勢的口服標靶治療。這些進展正在加速針對B細胞耗竭和多種白細胞白細胞介素通路等機制的標靶開發項目，而JAK抑制劑選擇性的提高也促使人們重新評估其風險獲益比及其在治療流程中的地位。

評估到 2025 年關稅制度變化對供應鏈韌性、製造在地化和商業性准入策略的綜合影響。

貿易和關稅體系的政策變化可能對全球醫藥供應鏈的經濟和物流產生重大影響，預計到2025年，累積效應正迫使產業相關人員重新評估其採購、生產和定價策略。某些原料和成品關稅的提高加劇了依賴跨境分銷活性藥物成分、生物製藥組分和特種包裝材料的製造商的成本壓力。對於需要複雜低溫運輸物流和多成分供應鏈網路的治療方法，這些壓力尤其嚴峻。

綜合細分分析揭示了藥物類別、作用機制、給藥途徑、適應症、分銷和最終用戶方面的差異如何影響策略和營運挑戰。

市場區隔為評估臨床差異化和商業性機會的契合點提供了一個切實可行的觀點。依藥物類別分類，市場包括生物製藥、生物相似藥和小分子藥物，其中生物製藥可細分為融合蛋白、單株抗體和胜肽類藥物。這些區分對於生產複雜性、監管路徑和生命週期管理策略至關重要。依作用機制，療法可分為B細胞清除劑、白細胞介素抑制劑、JAK抑制劑和TNF抑制劑，其中白細胞介素抑制劑又可細分為IL-17、IL-23和IL-6抑制劑，JAK抑制劑又可細分為JAK-1、JAK-1/2和JAK-3抑制劑。這種作用機制的細分有助於標靶選擇、安全性監測以及在特定適應症中建立競爭優勢。

美洲、歐洲、中東和非洲以及亞太地區的監管環境、支付方和生產環境有何不同？這些差異又如何影響各地區的市場進入與上市策略？

區域趨勢以不同的方式影響研發重點、監管路徑、支付方行為和打入市場策略。在美洲，定價和報銷討論深受支付方主導的處方藥清單管理以及日益重視基於價值的契約的影響，而商業性成功往往取決於健全的患者支持計劃和與專科藥房的合作。在歐洲、中東和非洲市場，法律規範和定價壓力呈現複雜多元的格局。集中化的監管路徑和聯合採購機制與各國不同的報銷標準並存，這為戰略定價和適應性上市順序創造了機會，並儘可能利用區域監管協調。亞太市場的特點是監管環境快速變化、本地產能不斷擴大以及支付方環境多元化。打入市場策略通常強調成本效益高的生產、與本地契約製造的合作以及反映當地醫療服務模式的客製化准入計劃。

強調科學差異化、卓越製造和以支付方為導向的證據產生的競爭需求正在塑造整個治療領域的企業策略。

自體免疫療法領域的競爭格局由大型生物製藥公司、專業生物技術創新企業、契約製造組織 (CMO) 以及新興生物相似參與企業組成。主要企業正投資於下一代生物製藥、精準靶向小分子藥物以及將治療與數位化用藥依從性支持和監測解決方案相結合的方案。策略聯盟、授權協議和定向推廣授權仍然是加速產品線多元化和獲取新型作用機制的常用策略，而無需承擔新藥研發的全部成本。

領導者可採取切實可行的策略步驟，加強價值鏈、證據產生和差異化價值提案，以加速招募並確保永續取得。

產業領導企業應優先考慮一系列切實可行的舉措，將科學進步轉化為永續的商業性價值。首先，透過多元化採購、擴大區域製造能力以及製定靈活的供應商協議來增強價值鏈韌性，從而降低關稅和物流中斷帶來的風險。其次，透過將真實世界結果和衛生經濟學終點納入臨床試驗，使臨床開發與支付方的證據需求保持一致，從而促進報銷談判並創造基於價值的合約機會。

透明地整契約儕審查研究、監管分析、臨床專家訪談和產品線概述，以支持強力的策略建議。

本執行摘要所依據的研究整合了多種證據來源，旨在提供可操作的策略洞察。研究人員對同行評審文獻、監管指導文件和公開的臨床試驗註冊資訊進行了二次證據審查，以梳理治療方法進展和安全性概況。此外，研究人員還與臨床醫生、衛生經濟學家、支付方和供應鏈專家進行了有針對性的專家訪談，以定性檢驗觀察到的趨勢並闡明其對營運的影響。最後，研究人員利用研發管線分析和作用機制映射，使研發方向與未滿足的需求和競爭定位一致。

這些結論結合了治療方法創新、營運韌性和與支付方的合作，為實現永續的醫療服務取得和商業性成功制定了連貫的藍圖。

自體免疫疾病治療市場正處於一個轉折點，科學進步、支付方審查和不斷演變的醫療模式相互交織，既帶來了風險，也帶來了機會。生物製藥、生物相似藥和標靶小分子藥物等領域的治療創新正在拓展治療選擇，並實現更個人化的治療，但這些進步也帶來了日益複雜的營運和商業挑戰。能夠將臨床差異化優勢與強大的生產能力、積極的支付方互動以及以患者為中心的醫療服務模式相結合的製造商，將最有可能獲得長期價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：自體免疫疾病治療市場：依藥物類別分類

  • 生物製藥
    • 融合蛋白
    • 單株抗體
    • 胜肽
  • 生物相似藥
  • 低分子化合物

第9章：自體免疫疾病治療藥物市場（依作用機轉分類）

  • B細胞清除劑
  • IL抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
    • IL-6抑制劑
  • JAK抑制劑
    • JAK1抑制劑
    • JAK1/2抑制劑
    • JAK3抑制劑
  • TNF抑制劑

第10章：自體免疫疾病治療市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 解決方案
    • 藥片
  • 腸外
    • 靜脈
    • 皮下

第11章：自體免疫疾病治療市場：依適應症分類

  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 狼瘡
  • 多發性硬化症
  • 銀屑病
    • 斑塊型乾癬
    • 乾癬性關節炎
  • 類風濕性關節炎

第12章：自體免疫疾病治療市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第13章：自體免疫疾病治療市場：依通路分類

  • 離線
  • 線上

第14章：自體免疫疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：自體免疫疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：自體免疫疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國自體免疫疾病治療市場

第18章：中國自體免疫疾病治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market was valued at USD 125.86 billion in 2025 and is projected to grow to USD 135.64 billion in 2026, with a CAGR of 8.45%, reaching USD 222.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 125.86 billion
Estimated Year [2026] USD 135.64 billion
Forecast Year [2032] USD 222.19 billion
CAGR (%) 8.45%

High-level orientation to clinical innovation, commercial complexity, and policy drivers that are jointly redefining autoimmune disease treatment strategies

This executive summary synthesizes current clinical, commercial, and policy developments that are reshaping the autoimmune therapeutics landscape. It synthesizes recent advances in therapeutic modalities, evolving mechanisms of action, shifts in routes of administration, and changing distribution and care-delivery models. The narrative highlights where scientific innovation intersects with reimbursement pressures, supply chain fragility, and heightened expectations for patient-centered care, producing a complex environment that demands agile strategic responses.

The introduction frames the competitive arena in terms of therapeutic differentiation and operational complexity. Biologic therapies have redefined standards of care across multiple indications, while biosimilars are increasing options for payers and providers. Simultaneously, oral small molecules and targeted inhibitors are altering patient preferences and adherence patterns. These dynamics unfold against a backdrop of intensified regulatory scrutiny, greater emphasis on real-world evidence, and payer initiatives designed to link outcomes to payment. The result is a market that rewards innovation in therapeutic efficacy and delivery, as well as excellence in commercialization, access strategy, and stakeholder engagement.

This section prepares the reader to evaluate subsequent analyses on technological shifts, policy impacts, segmentation insights, and regional differences. It prioritizes an integrated view that balances clinical promise with pragmatic considerations for manufacturing, distribution, and market access.

How scientific breakthroughs, payer pressures, and patient-centered delivery models are converging to redefine competitive and clinical dynamics in autoimmune therapeutics

The autoimmune therapeutics landscape is experiencing a series of transformative shifts driven by scientific advances, regulatory evolution, and changing patient and payer expectations. Therapeutic innovation is no longer limited to incremental improvements; it now includes novel biologic constructs, increasingly selective cytokine inhibitors, and oral targeted therapies that challenge traditional parenteral dominance. These advances have accelerated targeted development programs against mechanisms such as B cell depletion and multiple interleukin pathways, while the refinement of JAK inhibitor selectivity is prompting a reappraisal of benefit-risk trade-offs and positioning in treatment algorithms.

Concurrently, the maturation of biosimilar frameworks in several regulatory jurisdictions is altering competitive dynamics and accelerating cost-containment strategies among payers and health systems. This has prompted originator manufacturers to pursue differentiated value propositions, including novel formulations, extended-release technologies, and bundled service offerings that incorporate patient support and adherence tools. The shift toward patient-centric care models has also elevated the importance of route of administration; oral therapies are gaining traction for convenience and adherence potential, while subcutaneous self-administration and homecare-enabled intravenous services redefine where chronic treatment occurs.

Technological enablers such as remote monitoring, digital adherence platforms, and integrated data streams are enhancing real-world evidence generation and supporting outcomes-based contracting. Taken together, these shifts are remapping the competitive field, creating new entry points for novel modalities, and demanding cross-functional coordination between R&D, regulatory affairs, commercial strategy, and supply chain operations.

Assessing the compound effects of evolving tariff regimes on supply chain resilience, manufacturing localization, and commercial access strategies through 2025

Policy changes in trade and tariff regimes can materially affect the economics and logistics of global pharmaceutical supply chains, and the cumulative effects projected through 2025 have prompted industry participants to reassess sourcing, manufacturing, and pricing strategies. Increased tariff exposure on certain inputs and finished goods amplifies cost pressures for manufacturers that rely on cross-border flows for active pharmaceutical ingredients, biologics components, and specialized packaging. These pressures are particularly acute for therapies that require complex cold-chain logistics and multi-component supply networks.

In response, manufacturers are diversifying sourcing footprints, accelerating regional manufacturing investments, and negotiating more flexible supplier terms to insulate production from tariff volatility. Payers and health systems may respond to higher procurement costs by intensifying formulary management and prioritizing cost-effective alternatives, which could accelerate uptake of lower-cost biosimilars and incentivize negotiations around value-based agreements. At the same time, manufacturers are increasingly examining total cost of care narratives that encompass not just acquisition price but also patient outcomes, adherence benefits, and reductions in healthcare utilization, which can mitigate tariff-driven margin compression.

Logistically, tariffs contribute to longer lead times and higher inventory carrying costs as companies build buffer stocks to manage tariff-related interruptions. Regulatory and customs complexity can further slow product movement and complicate multi-jurisdictional clinical supply operations. Overall, the cumulative tariff environment through 2025 encourages strategies that prioritize supply chain resilience, closer collaboration with contract manufacturers and logistics partners, and proactive engagement with payers to preserve access while managing affordability concerns.

Integrated segmentation analysis revealing how drug class, mechanism, route, indication, distribution, and end-user distinctions drive strategic and operational imperatives

Segmentation provides a practical lens to evaluate where clinical differentiation and commercial opportunity align. Based on drug class, the market comprises biologics, biosimilars, and small molecules, with biologics further divided into fusion proteins, monoclonal antibodies, and peptides; these distinctions matter for manufacturing complexity, regulatory pathways, and lifecycle management strategies. Based on mechanism of action, treatments are clustered across B cell depleting agents, interleukin inhibitors, JAK inhibitors, and TNF inhibitors, with interleukin inhibitors further parsed into IL17, IL23, and IL6 inhibitors and JAK inhibitors categorized into JAK1, JAK1/2, and JAK3 inhibitors; this mechanistic granularity informs target selection, safety monitoring, and competitive positioning within specific indications.

Route of administration segmentation tracks oral and parenteral options, where oral forms include capsules, solutions, and tablets and parenteral forms encompass intravenous and subcutaneous delivery; route differences affect patient preference, adherence, clinic burden, and homecare feasibility. Indication-based segmentation addresses inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, and rheumatoid arthritis, noting that inflammatory bowel disease is further detailed into Crohn's disease and ulcerative colitis, while psoriasis includes plaque psoriasis and psoriatic arthritis; indication-level nuances dictate trial design, endpoints, and payer evidence requirements. Distribution channel segmentation distinguishes offline and online pathways, which impacts patient access models, specialty pharmacy engagement, and digital support services. Finally, end user segmentation covers clinics, homecare settings, and hospitals, and these care settings determine administration logistics, reimbursement codes, and provider training needs.

Interpreting these segmentation dimensions in combination highlights where clinical innovation can yield differentiated commercial returns and where operational investments will be necessary to translate therapeutic advances into accessible care. For example, a monoclonal antibody targeting an IL23 pathway intended for subcutaneous administration will have different commercialization imperatives than an oral JAK1 inhibitor, including distinct manufacturing priorities, patient support ecosystems, and distribution partnerships.

How divergent regulatory, payer, and manufacturing landscapes across the Americas, Europe Middle East & Africa, and Asia-Pacific demand tailored market access and launch strategies

Regional dynamics shape R&D priorities, regulatory pathways, payer behavior, and access strategies in distinct ways. In the Americas, pricing and reimbursement debates are heavily influenced by payer-driven formulary management and an increasing focus on value-based arrangements, while commercial success often hinges on robust patient support programs and specialty pharmacy integration. European, Middle Eastern, and African markets present a mosaic of regulatory frameworks and pricing pressures; centralized regulatory pathways and joint procurement mechanisms coexist with diverse national reimbursement criteria, creating opportunities for strategic pricing and adaptive launch sequencing that leverage regional regulatory harmonization where possible. Asia-Pacific markets are notable for rapidly evolving regulatory frameworks, growing local manufacturing capacity, and heterogeneous payer landscapes; market entry strategies commonly emphasize cost-efficient manufacturing, partnerships with regional contract manufacturers, and tailored access programs that reflect local healthcare delivery models.

Each regional cluster demands differentiated approaches to clinical development, regulatory engagement, and commercialization. The Americas may prioritize evidence packages that support outcomes-based contracting and demonstrate real-world impact on healthcare utilization, whereas the Europe, Middle East & Africa region often requires nuanced pricing strategies and engagement with multiple national agencies. Asia-Pacific strategies frequently balance accelerated regulatory approvals with scalable manufacturing and distribution partnerships to meet diverse access and affordability constraints. Recognizing these regional distinctions early in product planning enables optimized trial site selection, manufacturing footprint decisions, and launch sequencing that align with both clinical and commercial objectives.

Competitive imperatives emphasizing scientific differentiation, manufacturing excellence, and payer-aligned evidence generation that shape corporate strategies across the therapeutic landscape

Competitive dynamics across the autoimmune therapeutics space are characterized by a mix of large biopharma incumbents, specialized biotech innovators, contract manufacturing organizations, and emerging biosimilar entrants. Leading companies are investing in next-generation biologics, precision-targeted small molecules, and combination approaches that pair therapeutic agents with digital adherence or monitoring solutions. Strategic collaborations, licensing agreements, and targeted in-licensing remain common tactics to accelerate pipeline diversification and to access novel mechanisms without incurring the full costs of de novo discovery.

Manufacturing and supply chain capabilities are increasingly central competitive differentiators, particularly for complex biologics and therapies requiring cold-chain logistics. Firms that can demonstrate localized manufacturing, robust quality systems, and flexible supply architectures are better positioned to mitigate tariff and logistics risks and to support rapid scale-up. On the commercial front, value articulation and payer engagement are evolving into sophisticated, data-driven dialogues; companies that proactively generate and share real-world evidence and patient-reported outcomes are more likely to secure preferred formulary positions and to participate in outcomes-based arrangements.

Smaller companies and startups are leveraging niche differentiation, such as highly selective pathway targeting or novel delivery technologies, to create acquisition or partnership opportunities with larger players. Meanwhile, biosimilar entrants are intensifying price competition in established classes, prompting originator companies to pursue lifecycle strategies that emphasize differentiation through improved formulations, convenience, and integrated services. Overall, the competitive environment rewards integrated strategies that combine scientific differentiation, manufacturing excellence, and payer-centered value demonstration.

Actionable strategic moves for leaders to strengthen supply chains, evidence generation, and differentiated value propositions that accelerate adoption and ensure sustainable access

Industry leaders should prioritize a set of practical actions to convert scientific advances into sustainable commercial value. First, invest in supply chain resilience by diversifying sourcing, expanding regional manufacturing capabilities, and developing flexible supplier agreements that reduce exposure to tariff and logistics shocks. Second, align clinical development with payer evidence needs by embedding real-world outcomes and health-economic endpoints into trials, thereby facilitating reimbursement discussions and enabling value-based contracting opportunities.

Third, pursue differentiated product and service bundles that combine therapeutic efficacy with adherence support, digital monitoring, and patient education to capture a broader measure of value. Fourth, adopt a portfolio approach that balances high-margin biologics with strategically chosen biosimilar or small-molecule opportunities to preserve access in cost-sensitive markets. Fifth, tailor market entry and commercialization strategies by region, prioritizing regulatory pathways, local manufacturing partnerships, and distribution models that reflect the Americas, Europe, Middle East & Africa, and Asia-Pacific nuances.

Leaders should also formalize payer engagement plans early, using iterative evidence generation to refine value propositions and to negotiate innovative contracting models. Finally, invest in cross-functional capabilities-regulatory affairs, health economics, real-world evidence, and digital health integration-to ensure that scientific progress translates into durable clinical uptake and sustainable access across diverse care settings.

Transparent synthesis of peer-reviewed research, regulatory analysis, clinical expert interviews, and pipeline landscaping to support robust strategic recommendations

The research underpinning this executive summary synthesizes multiple evidence streams to deliver actionable strategic insight. Secondary evidence reviews were conducted across peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic advances and safety profiles. Targeted expert interviews with clinicians, health economists, payers, and supply chain specialists provided qualitative validation of observed trends and clarified operational implications. Pipeline landscaping and mechanism-of-action mapping were used to align R&D trajectories with clinical unmet needs and competitive positioning.

Comparative regulatory analysis examined approval pathways, biosimilar frameworks, and pricing mechanisms across major jurisdictions to identify access levers and potential barriers. Case study review of notable launches and market-access arrangements informed best-practice recommendations on payer negotiation and patient support program design. Limitations of the methodology include reliance on available public data where proprietary commercial intelligence was not accessible, and the inherently dynamic nature of clinical development and policy which may evolve after the cut-off for this analysis. Wherever possible, findings were triangulated across multiple sources and reviewed by subject-matter experts to enhance robustness and reduce bias.

The research adheres to principles of transparency and reproducibility: methods, inclusion criteria, and the types of expert inputs are documented, and the analysis emphasizes qualitative synthesis over quantitative projection to ensure practical relevance for decision-makers.

Concluding synthesis that links therapeutic innovation, operational resilience, and payer engagement into a cohesive blueprint for achieving durable access and commercial success

The autoimmune therapeutics landscape is at an inflection point where scientific progress, payer scrutiny, and evolving care models intersect to create both risk and opportunity. Therapeutic innovation across biologics, biosimilars, and targeted small molecules is expanding treatment options and enabling more personalized care, but these advances come with heightened operational and commercial complexity. Manufacturers that integrate clinical differentiation with resilient manufacturing, proactive payer engagement, and patient-centered delivery models will be best positioned to capture long-term value.

Regional variability in regulatory frameworks, payer priorities, and manufacturing capacity requires tailored strategies that align trial design, supply footprints, and market access tactics with local realities. The cumulative impact of tariff changes and supply chain disruptions underscores the need for strategic planning that balances cost management with uninterrupted patient access. Ultimately, success in this arena will depend on an organization's ability to translate scientific innovation into compelling value narratives supported by real-world evidence, while maintaining operational agility to adapt to policy and market shifts.

Stakeholders across R&D, commercial, regulatory, and supply chain functions must collaborate closely to convert insights into executable roadmaps that preserve access, demonstrate value to payers, and improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Fusion Proteins
    • 8.1.2. Monoclonal Antibodies
    • 8.1.3. Peptides
  • 8.2. Biosimilars
  • 8.3. Small Molecules

9. Autoimmune Disease Drugs Market, by Mechanism Of Action

  • 9.1. B Cell Depleting Agents
  • 9.2. Il Inhibitors
    • 9.2.1. Il17 Inhibitors
    • 9.2.2. Il23 Inhibitors
    • 9.2.3. Il6 Inhibitors
  • 9.3. Jak Inhibitors
    • 9.3.1. Jak1 Inhibitors
    • 9.3.2. Jak1/2 Inhibitors
    • 9.3.3. Jak3 Inhibitors
  • 9.4. Tnf Inhibitors

10. Autoimmune Disease Drugs Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Capsule
    • 10.1.2. Solution
    • 10.1.3. Tablet
  • 10.2. Parenteral
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Autoimmune Disease Drugs Market, by Indication

  • 11.1. Inflammatory Bowel Disease
    • 11.1.1. Crohn's Disease
    • 11.1.2. Ulcerative Colitis
  • 11.2. Lupus
  • 11.3. Multiple Sclerosis
  • 11.4. Psoriasis
    • 11.4.1. Plaque Psoriasis
    • 11.4.2. Psoriatic Arthritis
  • 11.5. Rheumatoid Arthritis

12. Autoimmune Disease Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare Settings
  • 12.3. Hospitals

13. Autoimmune Disease Drugs Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Autoimmune Disease Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Autoimmune Disease Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Autoimmune Disease Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Autoimmune Disease Drugs Market

18. China Autoimmune Disease Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca plc
  • 19.9. Baxter International Inc.
  • 19.10. Bayer AG
  • 19.11. Biogen Inc.
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Celgene Corporation
  • 19.14. Eli Lilly and Company
  • 19.15. Gilead Sciences, Inc.
  • 19.16. GlaxoSmithKline plc
  • 19.17. Johnson & Johnson
  • 19.18. Mallinckrodt plc
  • 19.19. Merck & Co., Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Regeneron Pharmaceuticals, Inc.
  • 19.23. Roche Holding AG
  • 19.24. Sanofi S.A.
  • 19.25. Sanofi S.A.
  • 19.26. Takeda Pharmaceutical Company Limited
  • 19.27. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY B CELL DEPLETING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK1/2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 263. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 304. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. NATO AUTOIMMUNE DISEASE D